Abstracts tagged "interleukins (IL) and macrophages"

Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 2245 • 2018 ACR/ARHP Annual Meeting
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Anthony M. Reginato¹, Changqi Sun², Elsaid A. Khaled³, Tannin A. Schmidt⁴, Olin D. Liang⁵ and Gregory D Jay⁶, ¹Division of Rheumatology, Rhode Island Hospital, Providence, RI, ²Division of Rheumatology, Rhode Island Hospital, Providence, MA, ³Department of Biomedical and Phramaceutical Science, Chapman University School of Pharmacy, Irvine, CA, ⁴Biomedical Engineering, University of Connecticut Health Center, Framington, CT, ⁵Division of Hematology/Oncology, Rhode Island Hospital, Providence, RI, ⁶Department of Emergency Medicine, Rhode Island Hospital, Providence, RI
Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including…
Abstract Number: 2144 • 2016 ACR/ARHP Annual Meeting
Functional Analysis of Macrophages in BehçEt’s Disease: C-C Chemokine Receptor Type 1 (CCR1) and IL-10 Are Implicated in Pathogenesis of the Disease
Hiroto Nakano¹, Yohei Kirino¹, Momoko Ohno¹, Kana Higashitani¹, Mitsuhiro Takeno², Ryusuke Yoshimi¹ and Hideaki Nakajima³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: The recent GWAS and subsequent studies have identified susceptible genes such as CCR1 and IL10 genes, suggesting pathological roles of macrophages in Behçet's disease…
Abstract Number: 509 • 2012 ACR/ARHP Annual Meeting
IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
A. Bikker¹, A.a. Kruize¹, F. Redegeld², W. de Jager³, F.P.J.G. Lafeber⁴ and J.A.G. van Roon⁵, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Pharmacology UU, Utrecht, Netherlands, ³Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].